SYK vs. ABT, ISRG, BSX, MDT, BDX, EW, DXCM, IDXX, RMD, and STE
Should you be buying Stryker stock or one of its competitors? The main competitors of Stryker include Abbott Laboratories (ABT), Intuitive Surgical (ISRG), Boston Scientific (BSX), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), and STERIS (STE). These companies are all part of the "health care equipment" industry.
Stryker (NYSE:SYK) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability, community ranking and analyst recommendations.
Stryker pays an annual dividend of $3.20 per share and has a dividend yield of 0.9%. Abbott Laboratories pays an annual dividend of $2.20 per share and has a dividend yield of 2.2%. Stryker pays out 36.5% of its earnings in the form of a dividend. Abbott Laboratories pays out 68.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
Stryker has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500.
Stryker has a net margin of 16.03% compared to Abbott Laboratories' net margin of 13.96%. Stryker's return on equity of 23.05% beat Abbott Laboratories' return on equity.
Abbott Laboratories has higher revenue and earnings than Stryker. Abbott Laboratories is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.
Stryker currently has a consensus target price of $370.50, indicating a potential upside of 8.61%. Abbott Laboratories has a consensus target price of $120.60, indicating a potential upside of 19.73%. Given Abbott Laboratories' higher probable upside, analysts clearly believe Abbott Laboratories is more favorable than Stryker.
In the previous week, Stryker had 1 more articles in the media than Abbott Laboratories. MarketBeat recorded 23 mentions for Stryker and 22 mentions for Abbott Laboratories. Stryker's average media sentiment score of 0.70 beat Abbott Laboratories' score of 0.61 indicating that Stryker is being referred to more favorably in the media.
77.1% of Stryker shares are owned by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are owned by institutional investors. 5.5% of Stryker shares are owned by insiders. Comparatively, 0.5% of Abbott Laboratories shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Abbott Laboratories received 29 more outperform votes than Stryker when rated by MarketBeat users. Likewise, 69.62% of users gave Abbott Laboratories an outperform vote while only 64.54% of users gave Stryker an outperform vote.
Summary
Stryker beats Abbott Laboratories on 14 of the 20 factors compared between the two stocks.
Get Stryker News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SYK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
